Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To evaluate effectiveness of nonpeptide angiotensin-2 subtype-1 receptor antagonist losartan in therapy of symptomatic congestive heart failure in patients with ischemic heart disease, 116 patients were examined at the age of 36-62 (mean age 50.6 +/- 4.22). They had angina pectoris of functional class II-III (according to CCS) and congestive heart failure of functional class II-III (according to NYHA). All the patients were randomized into two groups. 60 patients of group 1 received basic medication with nitrates, diuretic (on demand), digoxin and aspirin. 56 patients of group 2 received basic medication and losartan (cozaar, MSD, USA) in the dose 25 mg/day for 48 weeks. Echocardiographic monitoring of the treatment efficacy was made. The outcomes of the treatment evidence that losartan improves the patients' clinical status and heart failure functional class. For twelve weeks losartan reduced left ventricular and atrial dilation positively influencing the isometric inotropic indices. In 48 weeks losartan arrested progression of pathologic remodelling of the left ventricle and prevents depression of total myocardial contractility. Losartan's positive effect in restriction of negative evolution of cardiac failure manifests on the treatment week 3.
 ...
PMID:[Losartan in therapy of chronic heart failure]. 1072 50

The phase behavior of a binary system constituted of purified 1,3-dicaproyl-2-stearoyl-sn-glycerol (CSC) and 1,2-dicaproyl-3-stearoyl-sn-glycerol (CCS) was investigated at a very slow (0.1 degrees C/min) and a relatively fast (3.0 degrees C/min) cooling rate using differential scanning calorimetry (DSC), low resolution NMR, X-ray diffraction (XRD), and polarized light microscopy (PLM). Related forms of the beta' polymorph were detected for all mixtures as well as a beta form for CSC-rich mixtures. A double chain length (DCL) stacking of the non-mixed CCS-CCS and CSC-CSC phases and a triple chain length (TCL) stacking of mixed CCS-CSC structure were detected for the different beta' forms. The kinetic phase diagram demonstrated an apparent eutectic at the 0.5(CSC) composition when cooled at 0.1 degrees C/min and at the 0.25(CSC) composition when cooled at 3.0 degrees C/min. The application of a thermodynamic model based on the Hildebrand equation suggests that compounds CSC and CCS are not fully miscible. In addition, the miscibility changes according to the structure of the growing solid phase which is dependent on CSC molar ratio as well as on the kinetics. It was also shown that the miscibility is concentration dependent and that the solid phase, which is growing at conditions well away from equilibrium, is determined kinetically. The molecular interactions were found to be strong and to favor the formation of CSC-CCS pairs in the liquid state. CSC and CCS were also shown to be immiscible in the solid state. Depressions in solid fat content (SFC) were observed for both rates. Relatively complex networks made of needle-like, spherulitic and granular crystals were observed in the CSC/CCS system. A pure CSC phase was found to be instrumental in promoting a higher SFC, and more stable polymorphic forms. The microstructure was shown to be strongly dependent on the cooling rate and was linked to the different polymorphic forms observed by DSC and XRD. Correlations between SFC and the eutectic behavior have been observed for the 3.0 degrees C/min cooling rate, but not directly in the case of the 0.1 degrees C/min cooling rate, where slower kinetics which favors the metastable to stable phase conversion processes prevented the same shifts in behavior.
 ...
PMID:The binary phase behavior of 1,3-dicaproyl-2-stearoyl-sn-glycerol and 1,2-dicaproyl-3-stearoyl-sn-glycerol. 1880 94

Central sensitivity syndrome (CSS) consists of adaptive pathophysiological changes associated with neuroplasticity in some chronic pain disorders. It could be grouped in two main conceptual conditions: one includes those chronic pain patients without overt structural pathology such as fibromyalgia, and the other subgroup includes conditions with recognizable structural abnormalities, both somatic (osteoarthritis) and visceral (endometriosis). In order to understand the role of neuromodulators in CCS we aim to determine whether brain-derived neurotrophic factor (BDNF) and S100B are associated to specific chronic pain disorders. Serum BDNF and S100B were measured in chronic pain women with different diagnosis: 88 with osteoarthritis, 36 with endometriosis, 117 with fibromyalgia, 33 with chronic tension type headache and in 41 healthy controls. ANCOVA analysis followed by heteroscedasticity-consistent covariance matrix was performed to evaluate BDNF and S100B levels, adjusted for depression severity, pain levels and use of analgesics according different pathologies. Serum BDNF concentrations were higher and not different in patients with fibromyalgia and headache, the CSS group without structural pathology. In contrast, the concentrations of S100B were higher in patients with osteoarthritis and endometriosis, in comparison to controls, fibromyalgia and tensional headache patients. This study supports the hypothesis that BDNF and S100B neuromodulators present different serum levels according to the background disease associated to the chronic pain. These have the potential to be studied as markers of active disease or treatment evolution.
 ...
PMID:BDNF and serum S100B levels according the spectrum of structural pathology in chronic pain patients. 3110 Apr 26

A 38-year-old female with anomalous left coronary artery from the pulmonary artery presented with refractory angina (Canadian Cardiovascular Society [CCS] class 4). Having failed two previous internal mammary artery grafts to the left anterior descending artery and with no percutaneous revascularization options, she underwent coronary sinus reducer implantation, which improved her symptoms (CCS 0), quality of life, and corresponded to an improvement in ischemia on myocardial perfusion scanning. This case report describes an unusual case of refractory angina in the context of congenital heart disease, illustrates the benefit of this novel hourglass-shaped stent in improving ischemia, quality of life, depression and anxiety, and highlights the importance of managing these patients in multidisciplinary teams.
 ...
PMID:Implantation of a Coronary Sinus Reducer to Treat Refractory Angina in a 38-Year-Old with an Anomalous Left Coronary Artery and No Revascularization Options. 3200 99